Stan Berenshteyn
Stock Analyst at Wells Fargo
(2.10)
# 2,838
Out of 4,876 analysts
60
Total ratings
48.48%
Success rate
-8.11%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Stan Berenshteyn
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VEEV Veeva Systems | Maintains: Overweight | $285 → $300 | $283.53 | +5.81% | 6 | May 29, 2025 | |
| OMCL Omnicell | Maintains: Overweight | $35 → $37 | $29.56 | +25.19% | 16 | May 23, 2025 | |
| TDOC Teladoc Health | Maintains: Equal-Weight | $10 → $8 | $8.36 | -4.25% | 3 | May 8, 2025 | |
| GDRX GoodRx Holdings | Maintains: Overweight | $8 → $7 | $4.96 | +41.13% | 8 | Apr 29, 2025 | |
| HQY HealthEquity | Maintains: Overweight | $110 → $125 | $105.40 | +18.60% | 9 | Feb 26, 2025 | |
| DOCS Doximity | Maintains: Equal-Weight | $43 → $55 | $61.07 | -9.94% | 10 | Feb 7, 2025 | |
| HCAT Health Catalyst | Maintains: Overweight | $13 → $10 | $3.85 | +160.08% | 5 | Jan 21, 2025 | |
| AMWL American Well | Upgrades: Overweight | $15 | $7.99 | +87.73% | 3 | Jan 13, 2025 |
Veeva Systems
May 29, 2025
Maintains: Overweight
Price Target: $285 → $300
Current: $283.53
Upside: +5.81%
Omnicell
May 23, 2025
Maintains: Overweight
Price Target: $35 → $37
Current: $29.56
Upside: +25.19%
Teladoc Health
May 8, 2025
Maintains: Equal-Weight
Price Target: $10 → $8
Current: $8.36
Upside: -4.25%
GoodRx Holdings
Apr 29, 2025
Maintains: Overweight
Price Target: $8 → $7
Current: $4.96
Upside: +41.13%
HealthEquity
Feb 26, 2025
Maintains: Overweight
Price Target: $110 → $125
Current: $105.40
Upside: +18.60%
Doximity
Feb 7, 2025
Maintains: Equal-Weight
Price Target: $43 → $55
Current: $61.07
Upside: -9.94%
Health Catalyst
Jan 21, 2025
Maintains: Overweight
Price Target: $13 → $10
Current: $3.85
Upside: +160.08%
American Well
Jan 13, 2025
Upgrades: Overweight
Price Target: $15
Current: $7.99
Upside: +87.73%